Loading organizations...

§ Private Profile · Athens, GA, USA
Biotech company developing vaccines and biotherapeutics for disease prevention in honeybees, shrimp, mealworms.
Founded in 2018 by Annette Kleiser, Dalan Animal Health is an Athens, Georgia-based biotechnology company that develops vaccines and biotherapeutics for underserved invertebrate production animals, specifically focusing on honeybees, shrimp, and mealworms. The organization utilizes transgenerational immune priming technology, a biological process that allows maternal animals to pass essential immune modulators directly to their larvae before they hatch. In collaboration with researchers at the University of Georgia Innovation Hub, the enterprise developed the world's first commercially available honeybee vaccine to prevent infectious diseases within critical agricultural pollination populations. To scale its manufacturing and research operations, the venture-backed biotechnology company has raised a total of $10 million in seed funding. This financing includes a recent $4.5 million Series Seed 3 round led by Prime Movers Lab, alongside equity participation from the investment firm At One Ventures.
Dalan Animal Health has raised $13.7M across 4 funding rounds.
Dalan Animal Health has raised $13.7M in total across 4 funding rounds.
Dalan Animal Health is a U.S.-based agricultural biotechnology company developing innovative vaccines and preventive health products for pollinators like honeybees and aquaculture species like shrimp.[1][2][3] It serves commercial beekeepers, aquaculture farmers, and agricultural partners by addressing critical disease challenges that threaten colony health, crop pollination, and global food production, with its flagship USDA-approved honeybee vaccine against American Foulbrood marking a breakthrough in invertebrate immunization.[1][2][3] The company's proprietary Innate Immunity Platform enables broad-spectrum protection across species, reducing reliance on antibiotics and supporting sustainable agriculture; recent momentum includes a $3M seed round in 2025 to commercialize its shrimp vaccine and expand into poultry and other areas, alongside awards like TIME's Best Inventions and SVG THRIVE Global Impact Challenge winner.[3]
Dalan Animal Health was founded in 2018 by Dr. Annette Kleiser, a biologist with a PhD from Ludwig Maximilian University in Munich and over 25 years in biotechnology leadership, business development, and startups.[1][3][4] Kleiser launched the company to pioneer disease prevention in underserved production animals like honeybees and shrimp, where traditional vaccines were deemed impossible due to their invertebrate immune systems.[4] A pivotal moment came with the development and USDA approval of the world's first insect vaccine for honeybees, protecting against American Foulbrood and validating Dalan's platform; early traction built through collaborations with researchers and beekeepers, leading to expanded applications in shrimp vaccines against White Spot Syndrome Virus and Early Mortality Syndrome.[2][3][4] The leadership team includes experts like Dr. Linda Rhodes, a veterinarian with experience at Merck, Merial, and as founding CEO of public biotech firm Aratana Therapeutics.[4]
Dalan rides the wave of sustainable bioscience and agtech innovation, addressing pollinator decline (key to 35% of global crops) and aquaculture losses (shrimp as the world's largest seafood protein source) amid climate pressures and antibiotic resistance.[1][2][3] Timing is ideal with rising demand for regenerative agriculture, regulatory support like USDA approvals, and investor interest in food security tech, positioning Dalan to influence ecosystem-wide shifts toward vaccine-based disease control in invertebrates.[3] By reducing colony losses and enabling antibiotic-free farming, it supports global food chains, collaborates with beekeepers/researchers, and inspires platform expansions into poultry/vectors, amplifying biotech's role in climate-resilient production.[1][2][3]
Dalan is poised to commercialize its shrimp vaccine, secure global approvals, scale manufacturing, and extend its platform to poultry, additional aquaculture, and vector-borne diseases, fueled by recent seed funding and strategic board additions.[1][3] Trends like AI-driven biotech, sustainable protein demand, and ESG investing will accelerate its growth, potentially transforming invertebrate health markets worth billions. As a mission-driven leader from honeybee breakthroughs to multi-species impact, Dalan exemplifies how targeted bioscience fortifies the foundation of global food security.[2][3]
Dalan Animal Health has raised $13.7M in total across 4 funding rounds.
Dalan Animal Health's investors include Maureen Boyce, Harris Komishane, Ministerio de Ciencia e Innovaci, Prime Movers Lab, At One Ventures, CP Ventures, Regeneration.VC, Sony Innovation Fund, Emlyn Scott, Tom Chi, Ira Gordon, Annette Kleiser.
Dalan Animal Health has raised $13.7M across 4 funding rounds. Most recently, it raised $3.3M Grant / Other Equity in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 19, 2025 | $3.3M Grant | — | Maureen Boyce, Harris Komishane, Ministerio DE Ciencia E Innovaci | Announced |
| Jun 1, 2023 | $5M Seed | Prime Movers LAB | AT ONE Ventures, CP Ventures, Regeneration.VC, Sony Innovation Fund, Emlyn Scott | Announced |
| Sep 27, 2022 | $3.5M Seed | TOM CHI, IRA Gordon | — | Announced |
| Oct 6, 2021 | $1.9M Seed | — | Annette Kleiser, Linda Rhodes, Neal Carter, Peter Brøns Poulsen, Petteri Saarinen | Announced |